An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF Therapy

Inclusion Criteria: * RA for at least 1 year * Clear clinical signs of active RA in 1 knee joint * Meet ARA (1987) criteria for diagnosis of RA and ACR (1991) criteria for RA functional classes I, II, or III * Inadequate clinical response to a minimum of 3 months of therapy with anti-TNF-blocking agents * Taking background DMARDs for a minimum of 3 months and at stable doses for at least 28 days Exclusion Criteria: * Serious bacterial infection in last 3 months * History of TB * History of cancer within 5 years * Evidence of latent or active bacterial or viral infection * Intra-articular corticosteroids within 3 months * Exposure to live vaccines * Exposure to CTLA4Ig or BMS-188667 * Treatment with immunoadsorption column(s), mycophenolate mofetil, leflunomide, anakinra, cyclosporine, etanercept, adalimumab, infliximab, azathioprine, oral or parenteral gold, D-penacillamine, calcineurin inhibitors, cyclophosphamide or other alkylating agents